Parallax Volatility Advisers
EBS icon

Parallax Volatility Advisers’s Emergent Biosolutions EBS Stock Holding History

Parallax Volatility Advisers’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,166
Closed -$240K – 2663
2017
Q4 		$240K Buy
+5,166
New +$217K ﹤0.01% 2129

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parallax Volatility Advisers's EBS Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Emergent Biosolutions (EBS) in Q1 2018, closing a stake of 5,166 shares — an estimated $240K sold.

Parallax Volatility Advisers first reported a position in EBS in Q4 2017 and held it in 1 quarter. The position peaked at $240K in Q4 2017. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Emergent Biosolutions position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 5,166 Emergent Biosolutions shares in Q1 2018, an estimated $240K.
  • Parallax Volatility Advisers first reported a position in Emergent Biosolutions in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Emergent Biosolutions position peaked at $240K in Q4 2017.
  • 272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.